Entering text into the input field will update the search result below

CRISPR Therapeutics AG (CRSP) CEO Samarth Kulkarni Presents at Chardan's 5th Annual Genetic Medicines Conference (Transcript)

SA Transcripts profile picture
SA Transcripts

CRISPR Therapeutics AG (NASDAQ:CRSP) Chardan’s 5th Annual Genetic Medicines Conference Call October 4, 2021 2:00 PM ET

Company Participants

Samarth Kulkarni - Chief Executive Officer

Conference Call Participants

Geulah Livshits - Chardan

Geulah Livshits

Hello. And it's now my pleasure to introduce you to our next participant, Dr. Sam Kulkarni, Chief Executive Officer of CRISPR Therapeutics. Sam, thank you for joining us today. As a reminder to our audience, if you'd like to ask a question over the course of the discussion, just type it into the question box underneath the video player.

So Sam, maybe you can start off by giving us a couple of minutes of introductory comments on CRISPR Therapeutics, including any recent business highlights or pipeline progress and upcoming events that we should be looking out for.

Samarth Kulkarni

Thank you, Geulah for having this conference. We've been at this conference now for a number of years and always enjoyed all of the interactions, and the firesides.

We're almost seven years into the formation of CRISPR Therapeutics now, and it's been an incredible journey bringing this powerful platform to patients. From a portfolio standpoint, we've been very fortunate to bring a number of medicines to the clinic that can have a profound impact on patients starting with CTX001, which is a lead asset targeted towards sickle cell disease and beta thalassemia.

The data we've shown so far with CTX001 shows the curative potential off a CRISPR based therapy for patients suffering from these diseases. There's a lot more to go on in terms of how this therapy plays out. But so far, we've been very fortunate to have our trials move at a very rapid pace. We'll talk more about regulatory interactions and what the bar there is, but this is positioned as a leading therapy for patients suffering from sickle

Recommended For You

Comments (1)

"We do base editing........." that's the first time I heard that CRISPR Therapeutics plays in that space. Is anyone able to shed any more light on this?
To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.